An official website of the United States government
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Trial Status: enrolling by invitation
The goal of this clinical study is to learn more about the long-term safety,
effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel,
brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in
participants of Kite-sponsored interventional studies.
Inclusion Criteria
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF)
or an Informed Assent Form prior to any study-related assessments or procedures
being conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Additional locations may be listed on ClinicalTrials.gov for NCT05041309.
